Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes... Read More

Health Canada approves TRESIBA® for children with Type 1 diabetes... Read More

Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®... Read More

Global News

Press releases from the Denmark headquarters.


Visit the pressroom of the website for our headquarters in Denmark where you can access the latest corporate stock exchange announcements, an image library, interim and annual reports and other relevant communication from Novo Nordisk A/S.

For all media inquiries, please contact Corporate Communications:    

Tel: 905-629-6612

Email: KXYH@novonordisk.com

If you have concerns regarding any Novo Nordisk product, please call customer care at 1-800-465-4334 or email nnci-drugsafety@novonordisk.com. In the event of a medical emergency, contact your healthcare professional.